Angion Biomedica, a late-stage biopharmaceutical company, agreed to merge with Elicio Therapeutics, a developer of novel immunotherapies and vaccines. Financial terms were not disclosed. “The merger with Angion comes at an ideal time with ELI-002 now completing the dose escalation portion of Phase 1 clinical studies in patients. We believe Elicio is at the forefront of changing the tide regarding how cancers with these mutations, which account for 25% of human solid tumors, are treated. We believe this merger reflects the strength of the ELI-002 program, our pipeline, and the value-creating potential of our lymph node-targeting approach to treating cancer and other diseases by engaging lymph nodes, the ‘schoolhouse’ of the immune system," Robert Connelly, Elicio CEO.